ClinicalTrials.gg
CompletedNCT05876767Updated Sep 16, 2025

Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult Participants

A Phase 1 interventional study of SAR444336 and Placebo in Healthy Volunteer, sponsored by Sanofi. Completed at 2 sites in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Sanofi · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Oct 2021, registered May 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This phase 1 study will assess the safety and tolerability, and characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of SAR444336 in healthy subjects following single- and repeated-dose administrations as a first step in clinical development prior to administering this new investigational medicinal product (IMP) to patients.

Read the detailed description

The anticipated study duration per participant is up to 10 weeks in Part 1.

  • Screening: 2 to 28 days prior to dosing (Day -28 to Day -2)
  • Treatment period: Day -1 to Day 29 post dose including
  • Institutionalization: Day -1 until Day 8
  • Ambulant period including repeat PK and PD blood sampling and ambulant visits: Day 9 to Day 29
  • Follow-up period: Day 30 to Day 43

The anticipated study duration per participant is up to 17 weeks in Part 2.

  • Screening: 2 to 28 days prior to dosing (Day -28 to Day -2)
  • Treatment period: Day -1 to Day 57 (Q2W/3 doses or Q4W/2 doses) or Day -1 to Day 85 (Q4W/3 doses), or Day -1 to Day 50 (Q3W) including
  • Institutionalization: Day -1 until Day 3
  • Ambulant period including repeat PK and PD blood sampling, ambulant visits and 24 hours institutionalization after 2nd and/or 3rd dose: Day 4 to Day 57 (Q2W/3 doses, Q4W/2 doses), Day 4 to Day 85 (Q4W/3 doses) or Day 50 (Q3W)
  • Follow-up period: Day 58 to Day 71 (Q2W/3 doses or Q4W/2 doses), Day 71 to Day 85 (Q4W/3 doses) or Day 51 to Day 64 (Q3W)
02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants between 18 and 55 years of age inclusive.
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and .
  • Laboratory values within normal range unless the abnormality is considered not clinical relevant by the investigator. The following parameters, however, must be within normal range: count, and CRP. , AST, total (unless the participant has documented or suspected Gilbert syndrome) should be \<1.25 and serum creatinine should be \< ULN.
  • Eosinophils \<500 cells/µL
  • Normal vital signs after 10 minutes resting in supine position
  • Standard 12-lead ECG parameters after 10 minutes resting in supine position in the normal ranges and normal ECG tracing unless the Investigator considers an ECG tracing abnormality to be not .
  • Body weight between 50 - 110 kg (inclusive) and (BMI) between 18 - 30 kg/m2 (inclusive) at screening.
  • Only for part 2: Fitzpatrick skin type I - III

Exclusion criteria

Exclusion Criteria:

  • Any disease associated with immune system dysfunction.
  • Known polyethylene glycol allergy
  • Only for Part 2: Known seafood allergy
  • Any current active viral, bacterial or fungal infection or any medically relevant infection having occurred within 3 weeks before inclusion.
  • Any history or presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, , systemic, ocular, or infectious disease, or signs of acute illness that would pose an unacceptable risk to the subject in the opinion of the investigator.
  • Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only, more than twice a month).
  • Blood donation >500 mL within 2 months before inclusion.
  • Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure ≥30 mmHg within 3 minutes when changing from supine to standing position.
  • Presence or history of drug , or allergic disease diagnosed and treated by a physician, except for history of mild allergic diseases which are not active at the time of inclusion and considered not clinically relevant in the opinion of the investigator.
  • History or presence of drug or alcohol abuse.
  • Smoking regularly more than 10 cigarettes or equivalent per week, unable to stop smoking during the study (occasional smoker can be enrolled).
  • Excessive consumption of beverages containing xanthine bases.
  • Presence or history of any atopic disease.
  • for Part 1: Non-live booster COVID-19 vaccination within 14 days before randomization. First (and second, if applicable) COVID-19 vaccinations are not allowed within 4 weeks before randomization.
  • for Part 2: Non- including Covid-19: last administration of a vaccine within 4 weeks before randomization.
  • Live vaccines: Last administration of a vaccine within 3 months before randomization; Immunomodulatory medication within 60 days before screening.
  • Only for Part 2: Participants with known previous exposure to KLH.
  • Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication; any vaccination within the last 28 days (except COVID-19 booster vaccination) and any biologics (antibody or its derivatives) given within 4 months before inclusion.
  • Positive result on any of the following tests: surface (HBs Ag) antigen, antihepatitis B core antibodies (anti-HBc Ab), anti- virus (anti-HCV) antibodies, anti-HIV1 and anti HIV2 Ab.
  • Positive result on urine drug screen.
  • Positive alcohol breath test.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    SAR444336

    SAR444336

    Drug: SAR444336

  • Placebo comparator
    Placebo

    placebo

    Drug: Placebo

Interventions

  • DrugSAR444336

    Single or repeated dose subcutaneous injection

  • DrugPlacebo

    Single or repeated dose subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Part 1: Number of subjects with treatment-emergent adverse events (TEAEs)

    Clinical laboratory evaluations including eosinophils, procalcitonin, and c-reactive protein (CRP), Vital signs, 12-lead electrocardiogram (ECG)

    Time frame: Until Day 43

  2. Part 2: Number of subjects with treatment-emergent adverse events (TEAEs)

    Clinical laboratory evaluations including eosinophils, procalcitonin, and c-reactive protein (CRP), Vital signs, 12-lead electrocardiogram (ECG)

    Time frame: Until Day 85

Secondary outcomes

  1. Plasma PK parameters: Cmax

    Maximum plasma concentration observed

    Time frame: Until Day 29 and Day 85

  2. Plasma PK parameters: tmax

    Time to reach Cmax

    Time frame: Until Day 29 and Day 85

  3. Plasma PK parameters: AUClast

    Area under the plasma concentration versus time curve over the dosing interval from time 0 until the last concentration above the limit of quantification

    Time frame: Until Day 29 and Day 85

  4. Plasma PK parameters: AUC

    Area under the plasma concentration versus time curve extrapolated to infinity

    Time frame: Until Day 29 and Day 85

  5. Plasma PK parameters: t1/2z

    Terminal half-life

    Time frame: Until Day 29 and Day 85

  6. Plasma PK parameters: CL/F

    Apparent total body clearance after a single extravascular dose

    Time frame: Until Day 29 and Day 85

  7. Anti-SAR444336 antibodies

    Time frame: Until Day 29 and Day 85

07

Study locations

2 sites
  • Investigational Site Number :5280001
    Leiden, Leiden 2333 CL, Netherlands
  • Investigational Site Number :5280002
    Groningen, Provincie Groningen 9728 NZ, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Dec 2023, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2023
First posted
May 25, 2023
StartActual
Oct 15, 2021
Primary completionActual
Dec 12, 2023
CompletionActual
Dec 12, 2023
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05876767
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 25, 2023
Start date
Oct 15, 2021
Primary completion
Dec 12, 2023
Completion
Dec 12, 2023
Last update
Sep 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion